Amgen Earnings Preview: Hedge Fund Moves and Congress Trades

Amgen is set to announce quarterly earnings soon, expecting $9B in revenue and $5.16 EPS. Hedge fund trading shows mixed activity, with significant reductions by some and increases by others. Recent congressional trades add to the stock's watchlist.

Date: 03-02-2025

AI Rating: 6

Quarterly Earnings Expectations: The report indicates that Amgen is expected to release its earnings data, with analysts forecasting a revenue of $9,045,282,041 and earnings of $5.16 per share. This aligns with investor anticipation and could positively influence stock prices depending on actual results.
Hedge Fund Activity: There has been a notable fluctuation in hedge fund activity surrounding Amgen. Notably, 1,171 institutional investors added shares while 1,326 decreased their positions. The removal of over 4 million shares by PATHWAY FINANCIAL ADVISERS could signify declining sentiment. However, a notable addition of shares by VAN ECK ASSOCIATES CORP (+263.8%) suggests confidence from some investors. These contrasting activities may lead to volatility in Amgen's stock price as sentiment shifts.
Congressional Trading: The report highlights congressional trading activity, showing 2 purchases and 1 sale in the past 6 months. Notable transactions include Representative Virginia Foxx purchasing up to $15,000 and Representative Scott Franklin buying up to $100,000. These transactions may indicate insider confidence, potentially positively impacting Amgen's stock perception among investors.
Overall, the mixed hedge fund activity and recent congressional trades create a complex narrative surrounding Amgen. Investors may react strongly to the upcoming earnings announcement, impacting stock prices based on actual performance against the set expectations.

Stocks: AMGN